Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
4 minute read
  • FDA
  • News

Novavax Highlights Data From 3 Complementary Studies Of COVID-19 Beta Variant Strain Vaccine

By Benzinga Newsdesk
Today, 3:35 PM
- Recombinant spike protein antigen (rS-B.1.351) based on the Beta (B.1.351) virus lineage highly immunogenic in mice and produced neutralizing antibodies - Primates boosted with rS-B.1.351 induced strong neutralizing

NVAX

Read More
1 minute read
  • FDA
  • News

Enlivex Earlier National Institutes Of Health ClinicalTrials.gov Study Record Detail For Co.’s ‘Phase 2b…Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19…’

By Benzinga Newsdesk
Today, 3:35 PM
https://clinicaltrials.gov/ct2/show/NCT04922957

ENLV

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

Moderna Says No Link Between COVID-19 Jab And Heart Inflammation

By Vandana Singh
Today, 3:35 PM
Moderna Inc (NASDAQ:MRNA) says there is no “causal association” between its COVID-19 vaccine and cases of myocarditis or pericarditis, based…

BNTX

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News

Zynerba’s Zygel Improves Sleep In Children With Severe Epilepsies

By Vandana Singh
Today, 3:35 PM
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE)…

ZYNE

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News

Sanofi’s Sutimlimab Hits Endpoint Goal In Rare Anemia Study After FDA Rejection

By Vandana Singh
Today, 3:35 PM
Sanofi SA’s (NASDAQ:SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold…

SNY

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Government
  • Health Care
  • News

FDA Authorizes 10M JNJ COVID-19 Vaccine Doses, Asks To Discard 60M From Emergent Plant: NYT

By Vandana Singh
Today, 3:35 PM
The FDA has asked Johnson & Johnson (NYSE:JNJ) to discard 60 million doses of its COVID-19 vaccine manufactured at the…

EBS

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Legal
  • News

Eli Lilly’s Internal Probe Clears Its COVID-19 Drug Plant; Memo Says Company Did Not Make False Statements: Reuters

By Vandana Singh
Today, 3:35 PM
Eli Lilly and Co (NYSE:LLY) revealed last month that the U.S. Department of Justice (DOJ) issued a subpoena into its manufacturing…

LLY

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Penny Stocks
  • Small Cap

Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress

By Vandana Singh
Today, 3:35 PM
Aptose Biosciences Inc (NASDAQ:APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials – one in relapsed or…

APTO

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Small Cap

Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease

By Vandana Singh
Today, 3:35 PM
Forma Therapeutics Holdings Inc (NASDAQ:FMTX) announced new data from its ongoing Phase 1 trial of etavopivat (FT-4202) in sickle cell disease.…

FMTX

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Small Cap

Protagonist Stock Moves Higher As Rusfertide Shows Durability Of Effect, Symptom Improvements In Blood Cancer Trial

By Vandana Singh
Today, 3:35 PM
Protagonist Therapeutics Inc (NASDAQ:PTGX) has announced updated results from the ongoing Phase 2 study of rusfertide for polycythemia vera (PV), a…

PTGX

Posts navigation

Previous 1 … 1,031 1,032 1,033 … 1,053 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service